FUSEN PHARM (01652): "Paramevir Injection" approved for market.

FUSEN PHARM (01652) announced that its wholly-owned subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., has received approval from the China National Medical Products Administration for the market application of "Peramivir Injection," developed by the company. It is approved for the treatment of influenza A or B. "Peramivir Injection" is the only FDA-approved antiviral injection for influenza and the first neuraminidase inhibitor approved for the intravenous treatment of influenza A and B in China. It can be used for severe influenza and patients who cannot take oseltamivir orally, providing fast relief from fever and symptoms such as nasal congestion, runny nose, cough, and phlegm caused by influenza. Peramivir is a new generation neuraminidase inhibitor that selectively inhibits the neuraminidase of influenza A and B viruses, preventing mature viruses from leaving host cells and spreading within the body, thereby treating influenza. It can be used to treat patients of all ages with influenza A or B. "Peramivir Injection" is a second-class national medical insurance product recommended for the treatment of influenza A and B in multiple guidelines, including the "Diagnosis and Treatment Plan for Influenza," "Guidelines for the Diagnosis and Treatment of Adult Common Cold," "Expert Consensus on Antiviral Treatment for Adult Influenza," and "Expert Consensus on Diagnosis and Treatment of Children's Influenza." According to data from Minet, sales of peramivir-related formulations in China's three major terminals and six major markets are expected to exceed 800 million yuan by 2025. The launch of "Peramivir Injection" is another important product for the group, further enriching its product pipeline in the field of anti-infectives. This product will provide more treatment options for patients with influenza A or B.